Dr. David Bartlett | Surgical Oncology | Best Researcher Award

Dr. David Bartlett | Allegheny Health Network | United States

Dr. David L. Bartlett is a distinguished surgical oncologist and cancer researcher specializing in innovative cancer treatments. 🎗️ He earned his M.D. from the University of Texas Medical School at Houston and completed his residency at the Hospital of the University of Pennsylvania. 🏥 He further honed his expertise through fellowships at Memorial Sloan Kettering Cancer Center. Dr. Bartlett has held prestigious leadership roles at the National Cancer Institute, University of Pittsburgh, and Allegheny Health Network, where he currently serves as System Chair of the AHN Cancer Institute. His contributions to surgical oncology and cancer research have shaped modern treatment approaches. 🔬

Professional Profile:

ORCID

Suitability for Best Researcher Award

Dr. David L. Bartlett is an exceptional candidate for the Best Researcher Award due to his groundbreaking contributions to surgical oncology and cancer research. His extensive experience in oncologic surgery, innovative treatment methods, and leadership in major cancer institutions sets him apart as a leading figure in the field. His work has significantly advanced cancer treatment strategies, improving patient outcomes and shaping the future of oncology.

Education & Experience 🎓📜

B.A. – Rice University, Houston, Texas (1983) 🎓
M.D. – University of Texas Medical School at Houston (1987) 🩺
Residency – Surgery, Hospital of the University of Pennsylvania (1987-1993) 🏥
Fellowship – Surgical Oncology, Memorial Sloan Kettering Cancer Center (1993-1995) 🔬
Special Expert – Surgery Branch, National Cancer Institute (1995-1996) 🧬
Senior Investigator – National Cancer Institute (1996-2001) 🏥
Associate Professor – University of Pittsburgh (2001-2005) 📚
Chief, Surgical Oncology – University of Pittsburgh (2001-2011) 🏥
Bernard Fisher Endowed Professor of Surgery – University of Pittsburgh (2006-2020) 🎖️
System Chair – AHN Cancer Institute (2020-present) 🌍

Professional Development & Leadership 🏆

Dr. Bartlett has significantly advanced surgical oncology through leadership roles and contributions to professional societies. 🎗️ He has been actively involved in the Society of Surgical Oncology (SSO), serving as Vice President, President-Elect, and President. 🎖️ His work includes chairing the UPMC Robotic Oversight Committee, leading the Regional Cancer Therapies Annual Meeting, and contributing to the FDA’s Cellular, Tissues, and Gene Therapies Advisory Committee. 🏥 As an editorial board member for journals like Cancer Gene Therapy and Clinical Colorectal Cancer, he has influenced research directions. Currently, as System Chair of the AHN Cancer Institute, he continues to pioneer cancer treatment advancements. 🔬

Research Focus 🔍

Dr. Bartlett specializes in cancer immunotherapy, regional cancer therapies, and surgical oncology. 🎗️ His research explores gene and cellular therapies, hyperthermic intraperitoneal chemotherapy (HIPEC), and regional perfusion techniques to enhance cancer treatment. 🔬 His NIH-funded studies have led to groundbreaking approaches in treating peritoneal and advanced-stage malignancies. 🧬 He has played a key role in integrating robotics and precision medicine into oncological surgery. 🤖 His focus on personalized cancer treatments continues to impact global oncology practices. 🌍 Through his work, he has significantly improved patient outcomes and contributed to the evolution of cancer surgery. 🏥

Awards & Honors 🏅

Bernard Fisher Endowed Professor of Surgery – University of Pittsburgh (2006-2020) 🎖️
President – Society of Surgical Oncology (2019-2020) 🏆
Vice President – Society of Surgical Oncology (2017-2018) 🎗️
Editorial Board Member – Cancer Gene Therapy, Annals of Surgical Oncology 📖
Chair – UPMC Robotic Oversight Committee (2010-2014) 🤖
Treasurer – Society of Surgical Oncology (2014-2017) 💰
Board of Directors – James Ewing Foundation (2011-2018) 🏥
FDA Advisory Committee Member – Cellular, Tissues, and Gene Therapies (2014-present) 🧬

Publication Top Notes:

🧫 Intra-Tumoral CD8+:CD3+ Lymphocyte Density Ratio in Appendix Cancer Is a Tumor Volume- and Grade-Independent Predictor of Survival (2025) – Cancers 🏥
👁️ Precision in Tear Fluid Biomarker Discovery: Quantitative Proteomic Profiling of Small-Volume, Individual Samples Using Capillary Tube Collection (2025) – Biomedicines 🧪
🦠 Fecal Microbiome Composition Correlates with Pathologic Complete Response in Patients with Operable Esophageal Cancer Treated with Combined Chemoradiotherapy and Immunotherapy (2024) – Cancers 💊
🏥 Assessing the Long-Term Priorities of Pancreaticoduodenectomy Survivors (2024) – HPB ❤️
🧬 Intratumoral Delivery of Interleukin 9 via Oncolytic Vaccinia Virus Elicits Potent Antitumor Effects in Tumor Models (2024) –Cancer🔬

Assist. Prof. Dr. Keyang Xu | Macau University of Science and Technology | China

🎓 Dr. Keyang Xu is an Assistant Professor at the Faculty of Chinese Medicine, Macau University of Science and Technology. His research explores the intersections of oncology and metabolism, focusing on exosomes, proteomics, noncoding RNA, and natural therapies. With extensive experience from prestigious institutions like Hong Kong Baptist University and the University of Sydney, Dr. Xu is dedicated to advancing cancer research and translational medicine. He actively contributes as an editor for Frontiers in Oncology and the Journal of Taibah University for Science, driving scientific innovation in his field.

Suitability for Best Researcher Award

Dr. Keyang Xu is an exceptional candidate for the Best Researcher Award, given his pioneering contributions to oncology and metabolism. As an Assistant Professor at the Faculty of Chinese Medicine, Macau University of Science and Technology, Dr. Xu explores cutting-edge areas including exosomes, proteomics, noncoding RNA, and natural therapies, which are at the forefront of cancer research and translational medicine. His interdisciplinary approach bridges traditional Chinese medicine with modern biomedical science, paving the way for innovative cancer therapies.

Education & Experience:

🎓 Ph.D. in Chinese Medicine – Hong Kong Baptist University (2021-2024)

🎓 Visitor Scholar – Storr Liver Center, University of Sydney (2024)

🎓 Master’s Degree – Chinese & Western Clinical Medicine, Zhejiang Chinese Medical University (2016-2019)

🎓 Medicine Degree – Chengdu University of Traditional Chinese Medicine (2011-2016)

🧑‍🏫 Assistant Professor – Macau University of Science and Technology (2025-Present)

🔬 Research Assistant – Hong Kong Baptist University (2020-2024)

🩺 Physician – Lvkang Geriatric Rehabilitation Hospital, Hangzhou (2019-2020)

🩺 Physician – Xiwenbeiyuan Clinic, Hangzhou (2018-2019)

Professional Development:

🌏 Global Collaborations – Dr. Xu has collaborated internationally, including with renowned experts at the Storr Liver Center in Sydney.
📚 Editorial Roles – He actively contributes to scientific literature as an editor for Frontiers in Oncology and the Journal of Taibah University for Science.
🎓 Mentorship & Teaching – As an Assistant Professor, he guides future researchers and medical professionals.
🔬 Innovative Research – His research delves into the roles of exosomes, proteomics, noncoding RNA, and natural therapies in oncology and metabolism.
🤝 Professional Memberships – Active in the Good Practice in Traditional Chinese Medicine Research Association and Student Networks on EVs, fostering a collaborative scientific community.

Research Focus:

🧬 Oncology & Metabolism – Investigating the mechanisms linking cancer and metabolic disorders.
📦 Exosomes – Exploring the role of adipose tissue-derived exosomes in cancer metastasis and metabolic regulation.
🧪 Proteomics – Utilizing omics approaches to understand protein profiles influenced by obesity and metabolic changes.
🧬 Noncoding RNA – Investigating lncRNAs’ role in cancer progression and recurrence, particularly in HBV-related hepatocellular carcinoma.
🌿 Natural Therapy – Examining the therapeutic effects of natural compounds like Resveratrol on metabolic diseases and cancer.

Awards & Honors:

🏅 Research Grant – High-fat diet-enhanced colorectal cancer metastasis project (RC-FNRA-IG/20-21/SCM/01)

🏅 Research Grant – Effects of obesity on exosomal protein profiles (#2021Szvup131)

🏅 Research Grant – Molecular mechanism of LncBRM in HBV-related hepatocellular carcinoma (LSY19H030002)

🏅 Research Grant – Treating hyperuricemia-related NAFLD with Resveratrol (2014ZA090)

🏅 Research Grant – Clinical value of CHI3L1 in chronic hepatitis B (2019KY532)

Publication Top Notes:

“An Integration of RNA Sequencing and Network Pharmacology Approaches Predicts the Molecular Mechanisms of the Huo-Xue-Shen Formula in the Treatment of Liver Fibrosis” – 🧬📊

“Exosomes in Skin Flap Survival: Unlocking Their Role in Angiogenesis and Tissue Regeneration” – 🧫🩺

“Shared Genetic Links Between Nonalcoholic Fatty Liver Disease and Coronary Artery Disease” – 🧬❤️

“Exploring Tumor Heterogeneity in Colorectal Liver Metastases by Imaging: Unsupervised Machine Learning of Preoperative CT Radiomics Features for Prognostic Stratification” – 🧠🤖